Scientific image

Research & Development

As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority.

Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives. 

As people live longer, chronic conditions are on the rise. New viruses and diseases are emerging, while old enemies like cancer and neurodegenerative diseases remain. Sanofi is driven by the scope of these health challenges.

Innovative approaches

To unlock tomorrow’s science to develop the latest treatments, Sanofi’s R&D community is:

  • investing in multi-targeting therapies to tackle multiple diseases with a single drug;
  • working on combination therapies to make treatments more effective;
  • developing new biologics to produce precision medicines;
  • conducting breakthrough research to unlock the potential of gene therapy;
  • leveraging artificial intelligence and innovative digital technologies to empower patients to better manage chronic conditions.
R&D Pipeline

As of 30 June 2021, the drugs and vaccines in Sanofi's R&D pipeline include 83 projects, 35 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects represent new molecular entities as well as existing therapeutics being investigated for additional indications, or different formulations.

Research areas

Sanofi is investing in these research areas to find innovative solutions for patients:

Scientific image
Immunology & Inflammation

In recent years, Sanofi has led the science in immunology by introducing new treatment options for chronic, difficult-to-treat inflammatory diseases such as atopic dermatitis (eczema), asthma and rheumatoid arthritis. Sanofi is applying the most advanced research technologies and is focused on inflammatory conditions and autoimmune diseases with the highest unmet need. One of its key approaches is to develop multi-specific antibody therapies that combine multiple mechanisms of action in a single molecule and that target two or more molecular pathways simultaneously.

Scientific image
Despite incredible progress by scientists and drug developers over the last 20 years, cancer remains the second leading cause of death worldwide. Sanofi is combining its extensive heritage in small molecule research with new biologic capabilities to move cancer therapy forward. To achieve this, the company is leveraging multiple technology platforms, including monoclonal antibodies, messenger RNA (mRNA), and antibody drug conjugates - antibodies that are used as a unique delivery system to deliver drugs to where they are needed to combat cancer in the body.



Sanofi is developing new medicines built on patient insights and outstanding science to help the millions of people living with neurological disorders. Using revolutionary technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with conditions such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.
Scientific image
Rare Blood Disorders
With Ablynx and Bioverativ joining the Sanofi family, the company is now spearheading an industry-leading franchise to treat rare blood disorders. Sanofi continues to build on its legacy of innovation, from the development of the first extended half-life clotting factors for treating hemophilia A and B, using a range of technologies including further engineering clotting factor fusion proteins, small interfering RNA and gene therapy. It is developing novel therapies using insights into the complement mediated pathophysiology of other rare blood disorders, such as cold agglutinin disease, a chronic autoimmune hemolytic condition for which there are no approved therapies. Sanofi is also working to address the significant unmet medical need in sickle cell disease and other hemoglobinopathies with both small molecule and ex vivo gene editing approaches.


Scientific image
Rare Diseases

Sanofi has a strong foundation in lysosomal storage disorders: a group of rare, genetic conditions caused by enzyme deficiencies. Its teams are developing pioneering medicines for disorders such as Fabry, Gaucher, and Pompe diseases, and advancing toward new treatments for patients with GM2 gangliosidoses (Tay-Sachs disease, AB variant, and Sandhoff disease) and acid sphingomyelinase deficiency (ASMD). The insights gained from research into rare diseases can have applications for other diseases, for example leading to clinical studies of autosomal dominant polycystic kidney disease (ADPKD) and Alport syndrome.


Scientific image

Sanofi Pasteur is at the forefront of vaccine research and development, creating immunological solutions to prevent and cure diseases for every stage of life. It continuously harnesses new scientific knowledge and technologies to design safe and effective vaccines against complex diseases. Innovation is key to improving people's health around the world and also to the company's success. That is why it devotes more than €1 million to research and development every day. Sanofi Pasteur works every day to turn scientific breakthroughs and personal health insights into protective vaccines for people around the world.

Next Generation Approaches to Pioneer Tomorrow's Breakthrough Therapies

Next Generation Approaches to Pioneer Breakthrough Therapies

At Sanofi, we are developing medicines that have the potential to help transform patients’ lives by using the most advanced technology platforms to pioneer new innovative approaches to tackle diseases.